AstraZeneca selects new heart failure target with BenevolentAI
16 May 2024
Preview
Source: Pharmaceutical Technology
The strategic partnership between BenevolentAI and AstraZeneca began in 2019 and was expanded in 2022. Credit: Lutsenko_Oleksandr / Shutterstock.com.
AstraZeneca has incorporated a new target for heart failure treatment into its discovery portfolio through its ongoing collaboration with BenevolentAI.
This is the first target selected from the extended partnership between the companies.
The target was discovered by leveraging the AI-driven drug discovery platform of BenevolentAI and subsequently validated by AstraZeneca.
The strategic partnership between BenevolentAI and AstraZeneca began in 2019, initially focusing on identifying new treatments for idiopathic pulmonary fibrosis and chronic kidney disease.
In January 2022, the deal was expanded to include heart failure and systemic lupus erythematosus, highlighting the versatility of the Benevolent Platform across a range of therapeutic areas.
See Also:Food Allergy Awareness Week 2024: How can new treatments target an unmet need?
Preview
Source: Pharmaceutical Technology
Roche targets obesity market with early positive trial data
Preview
Source: Pharmaceutical Technology
The collaboration brings together the expertise of both companies, merging BenevolentAI’s platform and knowledge in biomedicine with AstraZeneca’s scientific and disease-specific capabilities.
This innovative approach to target identification combines the strengths of both organisations, leading to new discoveries.
Financial terms of both the initial and extended collaborations include upfront payments upon signing, research funding, potential discovery, development and commercial milestones.
BenevolentAI will receive tiered royalty payments on net sales of any products emerging out of the partnership upon their commercialisation.
AstraZeneca research and early development, cardiovascular, renal and metabolism head and senior vice-president Regina Fritsche Danielson stated: “Our ongoing collaboration with BenevolentAI has been instrumental in uncovering new insights into complex diseases such as CKD and heart failure.
“This shared expertise, combined with the power of AI, has the potential to identify the right therapeutic targets for patients with heart failure and help deliver the next generation of innovative therapies.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.